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Abstract We present clinical practice recommendations for
the treatment of children with Alport syndrome who are not
enrolled in clinical trials. Our goal is to promote early initia-
tion of a standard therapeutic approach that will facilitate
assessment of the safety and efficacy of the protocol. The
treatment protocol is based on the reduction of proteinuria,
intraglomerular pressure, and renal fibrosis via interference
with the renin–angiotensin–aldosterone system.
Keywords Alport syndrome . Proteinuria . Angiotensin-
converting enzyme inhibitor . Angiotensin receptor blocker .
Aldosterone inhibitor
Introduction
Investigation of Alport syndrome (AS) has elucidated the
roles of type IV collagen in basement membranes and de-
scribed the consequences of type IV collagen mutations for
renal, cochlear, and ocular structure and function. Research
studies employing animal models of AS have suggested inter-
ventions that may delay or reverse the renal effects of type IV
collagen mutations, but these approaches have yet to be pro-
spectively examined in human subjects with the disease.
While we wait for clinical trials to be organized, funded, and
carried to completion, children and adults with AS continue to
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progress towards end-stage renal disease (ESRD). What can
nephrologists offer in the meantime, and what can we learn
from clinical practice about the efficacy and safety of common
treatment approaches?
The Alport Syndrome Research Collaborative, currently
comprising investigators in Canada, China, France, Ger-
many, and the United States, has developed clinical practice
recommendations aimed at standardizing therapy for people
with AS who are not enrolled in clinical trials. It is our hope
that adoption of a consistent approach to therapy will allow
pooling and analysis of data about treatment responses and
efficacy.
Disclaimer
These are general clinical practice recommendations for off-
label therapy with inhibitors of the renin–angiotensin–aldo-
sterone system (RAAS) and may not be appropriate for all
children with AS. It is expected that practitioners will care-
fully consider a child’s baseline renal function in applying
these guidelines, will appropriately monitor for adverse
effects of therapy, and will adjust or discontinue therapy as
needed.
Natural history of untreated Alport syndrome
Genetics and genotype-phenotype correlations
Alport syndrome can be transmitted as an X-linked, autoso-
mal recessive or autosomal dominant disorder. About 80%
of individuals with AS have X-linked disease (XLAS) due
to mutations in the COL4A5 gene. Males with XLAS prog-
ress inexorably to ESRD, with ESRD risks of 50% by age
25, 90% by age 40, and nearly 100% by age 60 [1]. Age at
ESRD is strongly correlated with COL4A5 genotype in
males with XLAS [1–3]; risk of ESRD by age 30 is 90%
for deletions and nonsense mutations of COL4A5, 70% for
splicing mutations, and 50% for missense mutations. The
known strong genotype-phenotype correlation provides a
rationale for using COL4A5 genotype data to guide the
timing and intensity of intervention. In most families with
XLAS, age at ESRD is fairly similar among affected males.
In the absence of COL4A5 genotype data, timing of ESRD
can be predicted for a young affected male on the basis of
ESRD timing in older affected male relatives.
The effects of COL4A5 genotype on age at ESRD are not
observed in females with XLAS, likely due to the over-
whelming influence of X-inactivation [4]. In XLAS females,
the timing and intensity of intervention should be guided by
risk factors for progression to ESRD: proteinuria, gross
hematuria, and hearing loss [5, 6].
Autosomal recessive AS (ARAS) accounts for about 15%
of individuals with the disease and arises from mutations in
both alleles of either COL4A3 or COL4A4. Genotype-
phenotype data for ARAS is relatively sparse. In general,
individuals with ARAS carry a high risk of ESRD by age
30. Only about 5% of individuals with AS have autosomal
dominant disease (ADAS). As ADAS tends to progress at a
relatively slow velocity [7], there is less urgency to consider
initiation of intervention in childhood.
Clinicopathological correlations
In general, AS is characterized by genetically determined
dysfunction of the glomerular filter, mainly caused by muta-
tions in the collagens assembling the glomerular basement
membrane (GBM). In consequence, the earliest sign of
GBM filter dysfunction is hematuria followed by albumin-
uria and subsequent nonselective proteinuria in increasing
magnitude. Ultimately, not the GBM damage per se but the
pro-inflammatory and pro-fibrotic consequences both in the
tubulointerstitium and in the glomeruli resulting from pro-
gressive proteinuria, eventually lead to the development of
ESRD [8].
Overt proteinuria is typically absent in infant males with
XLAS. Age at identification of overt proteinuria shows inter-
familial variability and ranges from early childhood to ado-
lescence. In dogs with XLAS, a period of microalbuminuria
precedes the development of overt proteinuria and quantita-
tive increases in interstitial volume due to tubular atrophy and
fibrosis [9]. Dogs with XLAS exhibit increased proximal
tubular epithelial cell uptake of albumin, a process that has
been linked to cellular injury [9]. Preliminary data from the
Alport Syndrome Treatments and Outcomes Registry
(ASTOR) indicates that boys with AS also exhibit a transition-
al stage of microalbuminuria before overt proteinuria becomes
established (manuscript in preparation). It has yet to be dem-
onstrated that suppression of microalbuminuria has anti-
fibrotic effects in AS, although this is a reasonable hypothesis.
Measurements of cortical interstitial volumes in AS males
have shown that interstitial fibrosis is unusual before age 10
[10]. Cortical interstitial volumes become abnormal in many
AS males during the second decade of life, and are inversely
correlated with glomerular filtration rates [10]. These obser-
vations suggest that, (1) as in other chronic glomerulopathies,
interstitial fibrosis is a significant contributor to loss of renal
function, and (2) prevention of interstitial fibrosis in ASmales
may require intervention during childhood.
Therapeutic studies
Several therapies improve outcomes in animal models of AS,
including angiotensin-converting enzyme (ACE) inhibition
[11, 12], AT1-receptor blockade (ARB) [11, 12], inhibitors of
TGF-β1, matrix metalloproteinases, vasopeptidase A or HMG-
CoA reductase [13–16]; chemokine receptor 1 blockade [17],
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BMP-7 [18], stem cells [19–22], and irradiation [23]. However,
none of these approaches has been prospectively studied in
human AS populations.
In ARAS mice, initiation of ACE inhibitor therapy before
onset of proteinuria suppressed proteinuria and azotemia
and doubled length of survival [11], a therapeutic benefit
that has yet to be exceeded by any other intervention. A
smaller but still significant improvement in outcome was
achieved when ACE inhibition was started after onset of
proteinuria [11]. ACE inhibitor therapy begun before onset
of proteinuria lengthened survival in canine XLAS [24].
Retrospective analysis of registry data strongly suggests
that ACE inhibition delays ESRD and improves life expec-
tancy in AS patients in a time-dependent manner [25]. This
observation highlights the importance of early and accurate
diagnosis of AS, including specific genotyping whenever
feasible (for information on diagnostic methods in AS,
please see www.genereviews.org). Besides the beneficial
effects of RAAS blockade on outcomes in experimental
and human AS, there are additional compelling reasons to
recommend RAAS blockade in AS patients until a superior
therapy is identified. First, ACE inhibitor therapy at doses
that achieve suppression of proteinuria has been used with a
high degree of safety in children with chronic kidney dis-
ease [26, 27]. Further, these agents are widely available and
relatively inexpensive, making this therapy accessible to AS
patients worldwide.
Clinical trials
We recognize that a randomized clinical trial would be the
best way to evaluate the efficacy of ACE inhibition or any
other intervention in children with AS. We also recognize
that widespread adoption of our recommendations may re-
duce the pool of children who are eligible for clinical trials
of potential therapies for AS. Nevertheless, we encourage
eligible subjects and their families to consider participation
in clinical trials wherever and whenever possible. For ex-
ample, by the time this document is published, a clinical trial
of ACE inhibition in AS will be recruiting subjects residing
in Germany, or willing and able to travel to Germany (con-
tact: studie@alport.de; for information and to download
flyer see www.alport.de/EARLY_PRO-TECT). The goal of
this trial is to clarify if an early start of therapy (in patients
with isolated hematuria or microalbuminuria) delays renal
failure even more effectively than later onset of therapy (in
proteinuric patients) and above all if therapy at early stages
of AS is safe.
For those subjects unable to take part in clinical trials, we
believe that valuable efficacy and safety data can be collect-
ed if these subjects are treated according to a standardized
protocol. Currently, many children with AS are receiving
ACE inhibitor therapy in a non-standardized fashion, and
information about treatment responses is not being centrally
collected or analyzed. We believe that this represents a
wasted opportunity.
Treatment recommendations
Retrospective registry data strongly suggests that in subjects
with AS ACE inhibitor therapy initiated once proteinuria has
developed but while glomerular filtration rate is well pre-
served delays ESRD [25]. Similarly, in mice and dogs with
AS, interventions that delay the onset of proteinuria or reduce
established proteinuria prolong renal survival [11, 24]. Based
on these observations, and on the general consensus that
suppression of intraglomerular pressure and proteinuria is an
important component of the management of chronic glomer-
ular diseases, treatment of proteinuric AS patients with med-
ications that diminish proteinuria is recommended. Proteinuria
in children is defined as urine protein-creatinine ratio persis-
tently greater than 0.2 mg/mg in children over 2 years of age,
or urinary protein excretion greater than 4 mg/m2/h in a timed
collection [28, 29].
Cortical interstitial volume fraction (VvI/C) is a measure of
interstitial fibrosis and tubular atrophy [30]. There is a strong
inverse correlation between VvI/C and creatinine clearance in
boys with AS [10]. In these boys, VvI/C is typically within the
normal range during the first decade of life, when creatinine
clearance is also normal, but often begins to increase during
adolescence concurrent with declining creatinine clearance.
We presume that COL4A5mutations associated with relative-
ly rapid progression to ESRD, such as deletions, nonsense,
and splicing mutations, result in earlier onset and more ag-
gressive development of interstitial fibrosis and tubular atro-
phy. In dogs and mice with AS, the onset of proteinuria
precedes measurable increases in interstitial fibrosis. In light
of these observations, we recommend that in boys with AS
who have deletion, nonsense or splicing mutations, or who
have a family history of ESRD before age 30, monitoring of
urine protein excretion should begin early in life and that an
aggressive approach to initiating and escalating proteinuria-
suppressing therapies should be followed.
Based on these principles, we make the following rec-
ommendations aimed at preventing renal tubular epithelial
cell injury and suppressing fibrogenic processes in the renal
interstitium (see Fig. 1):
1. Monitoring for microalbuminuria and proteinuria should
be initiated by age 1 year in at risk children, or as soon as a
diagnosis of Alport syndrome is established, and repeated
at least annually.
2. Affected individuals with overt proteinuria (urine protein-
creatinine ratio persistently greater than 0.2 mg/mg, or
urinary protein excretion greater than 4 mg/m2/h in a
timed collection) should receive treatment.
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3. Treatment should be considered in affected boys with
microalbuminuria in whom the risk of ESRD by age 30 is
high, such as those with COL4A5 deletions, nonsense or
splicing mutations, or a history of ESRD before age 30 in
affected male relatives (Table 1). We recognize that access
to molecular genetic testing for Alport syndrome, and cov-
erage by insurers, is variable. We recommend that the
Alport genotype be determined whenever feasible, to facil-
itate identification of those at high risk of ESRD by age 30.
Target
The optimal target for lowering of urine protein levels is uncer-
tain. Our recommendations are based upon an arbitrary goal of a
urine protein:creatinine ratio of less than 0.5 mg/mg if the
baseline value is greater than 1.0 mg/mg, or a 50% reduction
if the baseline value is greater than 0.2 but less than 1.0. When
therapy is initiated in subjects with microalbuminuria, we rec-
ommend a target microalbumin:creatinine ratio of less than 50–
100 mg/g creatinine.
Proteinuria may persist at levels that exceed these targets,
despite maximum dosing of first- and second-line agents. In
these cases, we recommend continuing therapy, with adjust-
ment of dosing as indicated by growth and by renal function.
Agents
First line We chose angiotensin-converting enzyme (ACE)
inhibition as first-line therapy for several reasons. First, ACE
inhibition is the choice of most nephrologists for initial non-
immunologic therapy of proteinuric glomerular disease. Conse-
quently, practitioners have extensive experience with dosing
these agents and are familiar with their adverse effects. ACE
inhibitors are widely available and relatively inexpensive. The
Evaluation Study of Congestive Heart Failure and Pulmonary
Diagnosis
clinical: 1. hematuria 
 2. family history 
 3. Sensorineural deafness 
 4. ocular changes 
Kidney biopsy with EM, collagen IV IHC* 
Skin biopsy with type IV collagen IHC* 
Molecular genetics plus genetic counseling*













! Report to national or international registries !
* Depending upon availability and local practice
Fig. 1 Algorithm for
identifying children with
familial hematuria (Alport
syndrome or hematuria with
thin glomerular basement







Table 1 Recommendations for intervention based on urinary findings and anticipated disease course
Family history of early ESRD
(< 30 years) or severe
COL4A5 mutationa
Family history of late ESRD
(> 30 years) or less severe
COL4A5 mutationb
Male Female Male Female
Hematuria Intervention prior to onset of
microalbuminuria is not
recommended at this time
No No No
Hematuria + microalbuminuria Consider intervention Consider intervention No No
Hematuria + proteinuria Yes Yes Yes Yes
a Deletion, nonsense, or splicing mutation
bMissense mutation
ESRD end stage renal disease
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Artery Catheterization Effectiveness (ESCAPE) trial demon-
strated that ACE inhibition with ramipril is associated with very
low frequencies of adverse events in children with chronic
kidney disease and at least transient reductions in proteinuria
[26, 27]. Because of the ESCAPE experience, we chose ramipril
as the reference ACE inhibitor, and suggest equivalent doses of
other ACE inhibitors in Table 2. Finally, ramipril therapy started
before or after onset of proteinuria significantly prolonged sur-
vival in mice with autosomal recessive Alport syndrome, and its
effects were superior to those of candesartan [11, 12].
In the ESCAPE trial, reduction in proteinuria and preserva-
tion of glomerular filtration rate were correlated with ramipril’s
antihypertensive effect [26, 27]. Many of the Alport subjects in
whom therapy is initiated when they have developed micro-
albuminuria or mild proteinuria will be normotensive. If the
renoprotective properties of ACE inhibitors are primarily due
to their antihypertensive effects, the impact on Alport subjects
may be insignificant. However, ramipril delays proteinuria and
prolongs survival in normotensive autosomal recessive Alport
syndrome mice, indicating that other effects of ACE inhibition
are important in this model [11, 12].
Second line We propose two alternatives for second-line
therapy, angiotensin receptor blockade (ARB) and aldoste-
rone inhibition. For those nephrologists with experience
combining an ACE inhibitor with an ARB, ARB may be
the more comfortable, familiar approach. We suggest losar-
tan as the reference ARB, based on published experience in
children with chronic kidney disease [31]. In a recent study
of 30 proteinuric children with AS, losartan was found to
reduce proteinuria to a greater extent than placebo or amlo-
dipine [32]. We recommend a relatively low starting dose,
given that the ARB will be added to ACE inhibition (Ta-
ble 3). If an ARB is used instead of an ACE inhibitor, for
example because a patient tolerates ACE inhibition poorly, a
higher starting dose for the ARB would be appropriate.
There are a limited number of published reports regarding the
use of combination therapy with an ACE inhibitor and an ARB
in children with chronic proteinuric renal diseases. Ten children
with chronic kidney disease and persistent proteinuria, despite
maximal doses of an ACE inhibitor, exhibited a sustained
reduction in proteinuria after addition of losartan, with no sig-
nificant changes in blood pressure or glomerular filtration rate
[33]. In another small study of ten children with chronic kidney
disease and proteinuria that employed a cross-over design,
combination therapy with an ACE inhibitor and an ARB re-
duced proteinuria to a significantly greater extent than either
agent alone [34].
In a small group of patients with AS, combined therapy
with an ACE inhibitor and spironolactone suppressed pro-
teinuria to a greater extent than the combination of an ACE
inhibitor with an ARB [35]. Hyperkalemia was not encoun-
tered in this small group of patients. Increased aldosterone
levels (aldosterone escape) may contribute to persistent pro-
teinuria in Alport patients receiving ACE inhibitor therapy [36].
Aldosterone inhibition could be used as the initial second-line
agent, or as an alternative to ineffective ARB therapy (Table 4).
Potential adverse effects of therapy
Potential adverse effects of the therapeutic approach de-
scribed above include orthostatic hypotension, fetopathy in
ovulating females, hyperkalemia, reversible decline in glo-
merular filtration rate, and gynecomastia. In the ESCAPE
trial, only three of 352 children who received ramipril for at
least 6 months required discontinuation of therapy because
of orthostatic hypotension or hyperkalemia [24]. ACE inhib-
itors and ARBs should be used with caution in ovulating
females in order to avoid fetal injury.
Table 2 First-line therapy (angiotensin-converting enzyme inhibitor)
Agent Dose
Ramipril Starting dose of 1 to 2 mg/m2/day; increase
by 1 to 2 mg/m2/day every 3 months until
target UPC or adverse effect is attained;
maximum dose 6 mg/m2/day
Enalapril 2 × Ramipril dose (2 to 4 mg/m2/day)




Cilazapril 1 × Ramipril dose (1 to 2 mg/m2/day)
Perinopril
Trandolapril 0.5 × Ramipril dose (0.5 to 1 mg/m2/day)
Table 3 Second-line therapy (angiotensin receptor blocker)
Agent Dose
Losartan 12.5 mg/m2/day; double dose every 3 month
until target UPC or adverse effect is attained;
maximum dose 50 mg/m2/day
Candesartan 0.2 × Losartan dose (6.25 mg/m2/day)
Irbesartan 3 × Losartan dose (37.5 mg/m2/day)
Telmisartan 0.8 × Losartan dose (10 mg/m2/day)
Valsartan 1.5 × Losartan dose (18.75 mg/m2/day)
Epresartan 12 × Losartan dose (150 mg/m2/day)
Table 4 Second-line therapy (aldosterone antagonist)
Agent Dose
Spironolactone 25 mg daily for subjects 10–20 years of age;
consider lower starting dose in children
less than 10 years of age
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In the ONgoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET) study, the com-
bination of ramipril and telmisartan resulted in increased risk of
adverse renal outcomes (doubling of serum creatinine and re-
quirement for dialysis), hypotensive symptoms, syncope, and
hyperkalemia, compared to ramipril monotherapy [37]. Subjects
who received combination therapy also had an increased risk of
mortality, although not statistically significant [37]. The rele-
vance of the results of the ONTARGET study, in which study
subjects had a mean age of 66 years and were at high risk for
cardiovascular events due to vascular disease or diabetes, to
children and young adults with Alport syndrome is unclear.
Chronic administration of spironolactone is associated with
an increased incidence of serum potassium greater than
5.5 mEq/l (about 3% of subjects participating in clinical trials),
gynecomastia (about 5% of patients), and acute renal insuffi-
ciency (1–5% of subjects) [38]. We recommend regular mon-
itoring of serum potassium and creatinine levels in treated
Alport patients, especially those receiving combination therapy.
Reporting of treatment experience
We are in the process of developing an online reporting tool
that will allow practitioners to upload de-identified informa-
tion regarding treatment responses to a secure site. Once the
tool is in place, we will assist interested practitioners in
obtaining local IRB approval for participation. We will use
listservs and blast e-mails from the Alport Syndrome Treat-
ments and Outcomes Registry to announce the availability of
the site. In the meantime, we encourage practitioners to share
treatment experiences via e-mail with Dr. Kashtan.
Acknowledgements The Alport Syndrome Treatments and Outcomes
Registry (C.K., M.G., M.R., C.L.) receives support from private donors and
theAlport Syndrome Foundation (www.alportsyndrome.org). The European
Alport Registry is supported by the Association pour l’Information et la
Recherche sur les Maladies Rénales Génétiques (AIRG) (to O.G.) and the
KfH Foundation Preventive Medicine (Fritz-Scheler Stipendium of the
German Society of Nephrology) (to O.G.). The EARLY PRO-TECTAlport
trial is funded by the German Ministry of Education and Research (O.G.).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G,
Renieri A, Weber M, Gross O, Netzer K-O, Flinter F, Pirson Y,
Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P,
Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J,
Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syn-
drome: natural history in 195 families and genotype-phenotype
correlations in males. J Am Soc Nephrol 11:649–657
2. Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M (2002)
Meta-analysis of genotype-phenotype correlation in X-linked
Alport syndrome: impact on clinical counseling. Nephrol Dial
Transpl 17:1218–1227
3. Bekheirnia MR, Reed B, GregoryMC,McFann K, Shamshirsaz AA,
Masoumi A, Schrier RW (2010) Genotype-phenotype correlation in
X-linked Alport syndrome. J Am Soc Nephrol 21:876–883
4. Rheault MN, Kren SM, Hartich LA, Wall M, Thomas W, Mesa
HA, Avner P, Lees GE, Kashtan CE, Segal Y (2010) X-
inactivation modifies disease severity in female carriers of murine
X-linked Alport syndrome. Nephrol Dial Transplant 25:764–769
5. Grunfeld J-P, Noel LH, Hafez S, Droz D (1985) Renal prognosis in
women with hereditary nephritis. Clin Nephrol 23:267–271
6. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G,
Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y,
Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz
JM, Schroder C, Sanak M, Carvalho MF, Saus J, Antignac C,
Smeets H, Gubler MC (2003) X-linked Alport syndrome: natural
history and genotype-phenotype correlations in girls and women
belonging to 195 families: a "European Community Alport Syn-
drome Concerted Action" study. J Am Soc Nephrol 14:2603–2610
7. Pochet JM, Bobrie G, Landais P, Goldfarb B, Grunfeld J-P (1989)
Renal prognosis in Alport’s and related syndromes: influence of
the mode of inheritance. Nephrol Dial Transpl 4:1016–1021
8. Gross O, Kashtan CE (2009) Treatment of Alport syndrome:
beyond animal models. Kidney Int 76:599–603
9. Vinge L, Lees GE, Nielsen R, Kashtan CE, Bahr A, Christensen EI
(2010) The effect of progressive glomerular disease on megalin-
mediated endocytosis in the kidney. Nephrol Dial Transplant
25:2458–2467
10. Kashtan CE, Gubler MC, Sisson-Ross S, Mauer M (1998) Chro-
nology of renal scarring in males with Alport syndrome. Pediatr
Nephrol 12:269–274
11. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K,
Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril
therapy delays renal failure and reduces renal fibrosis in COL4A3-
knockout mice with Alport syndrome. Kidney Int 63:438–446
12. Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K,
Bloch W, Smyth N, Weber M (2004) Antifibrotic, nephroprotec-
tive potential of ACE inhibitor vs AT1 antagonist in a murine
model of renal fibrosis. Nephrol Dial Transplant 19:1716–1723
13. Sayers R, Kalluri R, Rodgers KD, Shield CF, Meehan DT, Cosgrove
D (1999) Role for transforming growth factor-beta 1 in Alport renal
disease progression. Kidney Int 56:1662–1673
14. Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S,
Weber M (2005) Nephroprotection by antifibrotic and anti-
inflammatory effects of the vasopeptidase inhibitor AVE7688.
Kidney Int 68:456–463
15. Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP,
Werner MC, Shield CF, Werb Z, Kalluri R (2006) Stage-specific
action of matrix metalloproteinases influences progressive hered-
itary kidney disease. PLoS Med 3:e100
16. Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S,
Gross O (2007) Nephroprotective effect of the HMG-CoA-reductase
inhibitor cerivastatin in a mouse model of progressive renal fibrosis
in Alport syndrome. Nephrol Dial Transplant 22:1062–1069
17. Ninichuk V, Gross O, Reichel C, Kandoga A, Pawar RD, Ciubar R,
Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema
G, Murphy PM, Gao J, Henger A, Kretzler M, Horuk R, Weber M,
Krombach F, Schlondorff D, Anders H (2005) Delayed chemokine
receptor 1 blockade prolongs survival in collagen 4A3-deficient
mice with Alport disease. J Am Soc Nephrol 16:977–985
18. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller
GA, Kalluri R (2003) Bone morphogenic protein-7 inhibits progres-
sion of chronic renal fibrosis associated with two genetic mouse
models. Am J Physiol Renal Physiol 285:F1060–F1067
10 Pediatr Nephrol (2013) 28:5–11
19. Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E,
Buchstaller A, Huss R, Akis N, Schlondorff D, Anders HJ
(2006) Multipotent mesenchymal stem cells reduce interstitial
fibrosis but do not delay progression of chronic kidney disease in
collagen4A3-deficient mice. Kidney Int 70:121–129
20. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R
(2006) Bone-marrow-derived stem cells repair basement mem-
brane collagen defects and reverse genetic kidney disease. Proc
Natl Acad Sci USA 103:7321–7326
21. Gross O, Borza DB, Anders HJ, Licht C, Weber M, Segerer S,
Torra R, Gubler MC, Heidet L, Harvey S, Cosgrove D, Lees G,
Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson
DR, Antignac C, Tryggvason K, Hudson B, Miner JH (2009) Stem
cell therapy for Alport syndrome: the hope beyond the hype.
Nephrol Dial Transplant 24:731–734
22. Lebleu V, Sugimoto H, Mundel TM, Gerami-Naini B, Finan E,
Miller CA, Gattone VH, Lu L, Shield CF, Folkman J, Kalluri R
(2009) Stem cell therapies benefit Alport syndrome. J Am Soc
Nephrol 20:2359–2370
23. Katayama K, Kawano M, Naito I, Ishikawa H, Sado Y, Asakawa
N, Murata T, Oosugi K, Kiyohara M, Ishikawa E, Ito M, Nomura S
(2008) Irradiation prolongs survival of Alport mice. J Am Soc
Nephrol 19:1692–1700
24. Grodecki KM, Gains MJ, Baumal R, Osmond DH, Cotter B, Valli
VE, Jacobs RM (1997) Treatment of X-linked hereditary nephritis
in Samoyed dogs with angiotensin-converting enzyme inhibitor. J
Comp Pathol 117:209–225
25. Gross O, Licht C, Anders H, Hoppe B, Beck B, Tonshoff B,
Hocker B, Wygoda S, Ehrich J, Pape L, Konrad M, Rascher W,
Dotsch J, Muller-Wiefel D, Hoyer P, Knebelmann B, Pirson Y,
Grunfeld J, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R,
Friede T, Lange K, Muller GA, Weber M (2012) Early
angiotensin-converting enzyme inhibition in Alport syndrome
delays renal failure and improves life expectancy. Kidney Int.
doi:10.1038/ki.2011.407
26. Wuhl E, Mehls O, Schaefer F (2004) Antihypertensive and anti-
proteinuric efficacy of ramipril in children with chronic renal
failure. Kidney Int 66:768–776
27. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A,
Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A,
Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM,
Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-
Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T,
Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi
L, Mehls O, Schaefer F (2009) Strict blood-pressure control and
progression of renal failure in children. N Engl J Med 361:1639–1650
28. Elises JS, Griffiths PD, Hocking MD, Taylor CM, White RH
(1998) Simplified quantification of urinary protein excretion in
children. Clin Nephrol 30:225–229
29. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A,
Ingelfinger J (2000) Evaluation and management of protein-
uria and nephrotic syndrome in children: recommendations
from a pediatric nephrology panel established at the National
Kidney Foundation Conference on Proteinuria, Albuminuria,
Risk, Assessment, and Elimination (PARADE). Pediatrics 105:1242–
1249
30. Lane PH, Steffes MW, Fioretto P, Mauer SM (1993) Renal inter-
stitial expansion in insulin-dependent diabetes mellitus. Kidney Int
43:661–667
31. Ellis D, Moritz M, Vats A, Janosky JE (2004) Antihypertensive
and renoprotective efficacy and safety of losartan. Am J Hypertens
17:928–935
32. Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW,
Le Bailly De Tilleghem C (2011) Efficacy and safety of losartan in
children with Alport syndrome – results from a subgroup analysis
of a prospective, randomized placebo- or amlodipine-controlled
trial. Nephrol Dial Transplant 28:2521–2526
33. Seeman T, Pohl M, Misselwitz J, John U (2009) Angiotensin
receptor blocker reduces proteinuria independently of blood pres-
sure in children already treated with angiotensin-converting en-
zyme inhibitors. Kidney Blood Press Res 32:440–444
34. Lubrano R, Soscia F, Elli M, Ventriglia F, Raggi C, Travasso E,
Scateni S, Di Maio V, Versacci P, Masciangelo R, Romero S
(2006) Renal and cardiovascular effects of angiotensin-
converting enzyme inhibitor plus angiotensin II receptor antagonist
therapy in children with proteinuria. Pediatrics 118:e833–e838
35. Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K,
Przybyslaw Krol R, Yoshikawa N, Matsuo M (2006) The effect of
aldosterone blockade in patients with Alport syndrome. Pediatr
Nephrol 21:1824–1829
36. Ku E, Campese VM (2009) Role of aldosterone in the progression
of chronic kidney disease and potential use of aldosterone block-
ade in children. Pediatr Nephrol 24:2301–2307
37. The ONTARGET Investigators (2008) Telmisartan, ramipril, or
both in patients at high risk for vascular events. N Eng J Med
358:1547–1559
38. Marrs JC (2010) Spironolactone management of resistant hyper-
tension. Ann Pharmacother 44:1762–1769
Pediatr Nephrol (2013) 28:5–11 11
